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Abstract  Objective: To review the correlation between prostate specific antigen (PSA) and Gleason score and Cav-1 for diagnosing prostate adenocarcinoma. 
 Methods: Data were collected from one hundred fifty-nine patients with 
prostate adenocarcinoma at the Department of Urology, Dr. Hasan Sadikin 
General Hospital in the period of January 2008–December 2010. The PSA 
levels were measured and classified into <4 ng/ml, 4–10 ng/ml, and >10 ng/
ml. The results were then analyzed and compared to the imunohistochemistry (caveolin-1) staining in the literature. The Gleason score was also noted and 
analyzed.  Results: This study confirmed that positive caveolin-1 expression was related 
to the clinical markers of disease progression and was predictive of poor 
clinical outcome after surgery. The PSA results showed that one hundred 
fourty-one adenocarcinoma patients had a PSA level of >10 ng/ml with 
Gleason score of gleason 5–6 as the most common score. However, there was 
no correlation between PSA and Gleason score and caveolin-1 for diagnosing prostate adenocarcinoma. Conclusions: Caveolin-1 cannot be used to measure Gleason and PSA score 
due to different markers that have various advantages and disadvantages to 
predict carcinoma prostate. Therefore, further studies are needed.
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Introduction 
Prostate adenocarcinoma is the malignancy 
that is most frequently found and also the second most common cause of death in men.1,2 
Adenocarcinoma of the prostate generally 
occurs at the age of >50 years but does not 
generate any clinical symptoms. Hence, most 
patients come at advanced stages. About 20% of the prostate adenocarcinoma is found 
incidentally in a histopatological procedure 
for examining the prostate gland based on the 
indication of hyperplasia.3
Adenocarcinoma prostate showed a high 
morbidity and mortality with a number of 
234.460 diagnosed and 27.350 passed away after diagnosed.4 A study found more than 230.000 new cases and 30.000 of them was death.5
Many ways were conducted to diagnose 
adenocarcinoma in its early stage, one of the 
strategy is by measuring the prostate specific 
antigen (PSA) level.6,7 Prostate specific antigen 
is a glicoprotein produced by the prostate 
gland with a normal level <4  ng/ml. A number 
of studies showed that PSA can be used to diagnose adenocarcinoma prostate with 75% accuration.8,9
Biopsy and histopatology are alternative 
ways to diagnose adenocarcinoma prostate. The Gleasson score can be used to determine 
when the histopatology analysis was carried out. The Gleasson score is an indication for 
the malignancy of adenocarcinoma prostate and important for a prognosis. The Gleason 
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score indicates prostate cancer based on its 
microscopic appearance. Thus, the higher the Gleasson score means it is more malignant 
but with poor prognosis. The five basic grade patterns are used to generate a histologic 
score and measure the Gleason score, which 
can be ranged from 2 to 10, by adding the 
primary and the secondary grade patterns. The 
primary pattern is the one that is predominant 
in the area, by a simple visual inspection. The 
secondary pattern is the second most common 
pattern. If only one grade is in the tissue 
sample, that grade is multiplied by two to give 
a score. According to the Gleason approach of 
1977, if the second grade is less than 3% of 
the total tumor, it is ignored, and the primary grade is again doubled to give the Gleason score (Fig. 1).5,10–14
Furthermore, a previous study identified 
and characterized clearly the overexpression of caveolin-1 (cav-1) gene occurring in a 
mouse model of prostate carcinoma and a human prostate carcinoma. In several clinical 
cases which determined the localization of 
prostate carcinoma showed cav-1 expression 
is a novel prognostic marker with independent predictive value of biochemical recurrence.12 
Adenocarcinoma is one of the major problems 
found in male aged above 50 years. Therefore, 
an early detection is very usefull to reduce 
morbidity for adenocarcinoma prostate.
Methods
One hundred fifty-nine data of patients were 
taken from medical records with inclusion 
criterion, patients who were diagnosed 
with adenocarcinoma in the period 2011–
2012 in Dr. Hasan Sadikin General Hospital, 
Bandung with symptoms of nocturia, urgency, 
retention urine and risk factor >50 years old. 
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Gleason Score from Lower to Higher.1 Gleason Pattern 1: Circumscribed Nodule 
of Closely Packed Uniform Glands, Gleason Pattern 2: Circumscribed Nodule 
of Loosely Packed Slightly Variable Glands, Gleason Pattern 3:  Single Glands 
of Variable Size and Density, with an Infiltrative Pattern, Each Separated by at 
Least a Strand of Stroma, Gleason Pattern 4: Ragged Infiltration with Poorly 
Formed Glands or Sheets and Cords of Fused Glands, Poorly Formed Glands 
Includes Small Nests of Cells with only a Rudimentary Formed Lumenal Space 
(almost Rosette Like), Gleason Pattern 5: Ragged Infiltrative Single cells, Cords 
or Sheets, Granular
Fig. 1
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They performed rectal tussae examination, 
measured the PSA level and histopathology to 
obtain the Gleason score. The prostate specific 
antigen level was measured and classified 
into <4 ng/ml, 4–10 ng/ml, >10 ng/ml. Those 
results were analyzed and compared into the 
imunohistochemistry (caveolin-1) of staining in the literature. The Gleason score was also noted (Fig 2).
Results
This study found that out of 156 patients, most of adenocarcinoma prostate patients occured 
in male who were >50 years old, with the highest incidence rate occuring in 75 patients 
aged 61–70 years (Fig. 3).
Additionally, the prostate specific antigen 
level was classified into <4 ng/mL usually 
normal in male, 4–10 ng/mL which is called 
the grey area, and >10 ng/mL which strongly 
indicates carcinoma. Apparently, one hundred 
fourty-one adenocarcinoma patients had PSA 
level >10 ng/ml (Fig. 4). Moreover, the Gleason 
score is classified into Gleason 2–4 which 
means good differentiated, Gleason 5–6 means 
moderate differentiated, Gleason 7–10 means 
poorly differentiated, and eighty patients had 
Gleason score 5–6 (Fig. 5).
Cav-1 immunoreactivity was detected in the 
cytoplasm of tumor cells in a granular pattern 
after comparing with immunohistochemistry 
from literature. The validity of the staining 
reactions was confirmed by the strong staining reactions characteristic of smooth muscle and 
endothelial cells within the stroma, although the proportion of cav-1-positive tumor cells were varied within individual specimens. 
Furthermore, cav-1 reactivity was not detected 
in histologically normal epithelial cells in 
areas adjacent to the tumor. The patient group 
with a PSA level >10 ng/mL was found to have the highest rate of cav-1-positive tumors. 
However, no significant correlation between 
cav-1 expression and preoperative serum 
PSA level was found (p=0.203, Spearman 
correlation test) and there was a tendency 
toward a higher incidence of cav-1 expression 
with a higher Gleason score, and no significant 
correlation between cav-1 expression and 
Gleason score was found (p=0.100; Spearman 
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correlation test). The description of Caveolin-1 
immunostaining in moderately differentiated prostate carcinoma cases and Caveolin-1 
expression as demonstrated by avidin-biotin 
complex immunohistochemical staining in 
moderately differentiated prostate carcinoma cases are shown (Fig. 6).20
Discussion 
Adenocarcinoma prostate generally occurs 
at the age of >50 years but does not generate 
any clinical symptoms. In the result, it showed that most of the patients with adenocarcinoma 
prostate are between 61–70 years old. The 
results have similarity with a previous study 
in dr. Moewardi Surakarta Hospital, the most 
common patients were aged 65–75 years.13 
Furthermore, another study in Barbados also revealed the most common age was between 
65–75 years old.14 This is similar to the theory that adenocarcinoma is related with age and 
usually occurs at the age >50 years old. 
The serum PSA screening has led to a dramatic increase in the diagnosis of prostate 
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Fig. 3 Age Distribution 
Fig. 4 Adenocarcinoma Prostat Correlation with PSA Level
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carcinoma as well as in the number of male 
undergoing radical prostatectomy in the past decade.15,16 In the United States, the number 
of newly diagnosed prostate carcinoma cases 
and cancer specific mortality appear to be 
declining; inspite of this, it is unclear whether these reductions are related to increased 
screening and earlier aggressive treatment, 
misclassification of cause of death, or more 
complex population dynamics.17 This PSA 
study showed similarity with a study from 
dr. Kariadi Semarang from 2000–2006 which 
found PSA >10 ng/mL in an adenocarcinoma 
patient. Thus, the finding in this study is 
similar to the previous study. The increase 
in serum PSA observed in prostate cancer 
patients is not due to increased expression of 
PSA on a cellular level. However, it is rather a tumor-associated disruption of the normal prostate tissue architecture that leads to the 
increased release of PSA into peripheral blood. 
Prostate specific antigen was first approved 
in 1986 by the Food and Drug Administration 
(FDA) to monitor response in patients treated 
for prostate cancer and subsequently as a 
diagnostic marker in 1994. Even at the time 
of its discovery, however, three inherent 
limitations of PSA as a biomarker were evident. 
Fig. 5 Adenocarcinoma Prostat Correlation with Gleason Score
Cav-1 in normal prostate was localized primarily to smooth muscle cells and 
endothelial cells in the stroma with negatively stained glandular epithelia (a). 
In contrast, cav-1 immunostaining was present in the cytoplasm of tumor cells 
(b)20
Fig. 6
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First, PSA is not regarded a prostate cancer 
specific antigen. Second, PSA does not reliably predict the grade or stage of prostate cancer 
at diagnosis. Third, PSA reflects tumor volume, 
however does not functionally contribute to 
the patophysiology of the tumor progression. 
Therefore, PSA does not distinguish clinically 
significance from insignificant prostate cancer. 
For these reasons, the PSA is most useful as a prognostic tool when combined with other clinicopathologic parameters.18
The findings of this study related to the 
Gleason score show similarity compared to 
the previous studies. Besides, a study showed that most of the patients had Gleason score 
5–6.19 It showed that most of adenocarcinoma prostates occured when the score is moderate 
differentiated and poorly differentiated. The 
study showed that adnocarcinoma prostate 
usually had no symptom meaning that patients 
did not realize suffering from adenocarcinoma. 
Meanwhile, the increase of the PSA level can be 
caused by hiperplasia prostate, inflammation 
or cancer in prostate, thus, the PSA level needs to be combined with rectal tusae which in 
adenocarcinoma usually has nodules in the 
prostate. Furthermore, the serum PSA levels, 
the Gleason score, and clinical stage have been shown to be useful in the preoperative 
prediction of final pathological stage. However, 
in the middle ranges of a given index, these 
indices lose predictive power. Therefore, additional individual predicting methods are 
needed, such as molecular markers.20
The cav-1 is a major structural coat protein 
of caveolae, specialized plasma membrane invaginations involved in multiple cellular 
functions including molecular transport, cell 
adhesion, and signal transduction. In clinically 
localized prostate cancer, the cav-1 is focally 
expressed by malignant epithelial cells. The 
cav-1 expression proportionally increases in 
high-grade primary tumors with lymph node 
metastases and in metastatic lymph nodes.18 
Univariate Cox proportional hazards analysis 
demonstrated that positive cav-1 expression was predictive of a shorter time to disease 
progression after the radical prostatectomy. 
The mechanism for increased expression of cav-1 in aggressive prostate cancer remains 
unclear, however, when compared with serum 
PSA, serum cav-1 more specifically identifies 
clinically aggressive disease. This likely reflects 
the fact that, unlike PSA, cav-1 biologically contributes to malignant progression and the development of castrate-resistance. For 
the same reason, serum cav-1 measurement 
may also prove useful as a biomarker in other 
prostate cancer disease states. Eventhough, 
there is significantly result between cav-1 
and the Gleason score. Obviously, there is no correlation between the serum cav-1 levels with the Gleason score using the Spearman 
correlation. This might be due to the lack of data.
In conclusion, the positive cav-1 expression 
is related to the clinical markers of the disease progression and is also predictive of a poor 
clinical outcome after the surgery. Therefore, 
there is no correlation between the PSA and the Gleason score with cav-1 for diagnose of adenocarcinoma prostate. It means that we 
cannot predict the Gleason score and PSA 
score only with cav-1. Due to those different 
markers advantages and disadvantages in 
predicting the carcinoma prostate, therefore, 
it need a further study.
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